|
|
Vaccine Detail
|
WT1 Analog Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: WT1 Analog Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007127
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: WT1
- WT1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The vaccine contained a mixture of four peptides, one of which contained a heteroclitic WT1-derived class I epitope to stimulate CD8 T-cell responses, two contained class II peptide sequences designed to stimulate CD4 T-cell responses, and the last contained both class I and class II epitopes. Each vaccine contained 200 μg of each peptide, for a total of 800 μg delivered in each injection, mixed 1:1 with an emulsion of Montanide ISA 51 VG adjuvant in phosphate-buffered saline, with a total volume of 1 mL (Brayer et al., 2015).
- Description: This is for Myeloma Cancer. A peptide vaccine comprised of an epitope of human Wilms tumor 1 (WT-1) with potential antineoplastic activity. WT-1, a transcription factor, is overexpressed in most types of leukemia and in some solid cancers. Vaccination with the WT-1 analog peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against WT-1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation (Brayer et al., 2015; NCIT_C64635).
|
| Host Response |
|
|
| References |
Brayer et al., 2015: Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. American journal of hematology. 2015; 90(7); 602-607. [PubMed: 25802083].
NCIT_C64635: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C64635]
|
|
